The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders
In the light of clinical experience in infantile onset Pompe patients, the immunological impact on the tolerability and long-term efficacy of enzyme replacement therapy (ERT) for lysosomal storage disorders has come under renewed scrutiny. This article details the currently proposed immunological mechanisms involved in the development of anti-drug antibodies and the current therapies used in their treatment. Given the current understanding of the adaptive immune response, it focuses particularly on T cell dependent mechanisms and the paradigm of using lymphocytic negative selection as a predictor of antibody formation. This concept originally postulated in the 1970s, stipulated that the genotypically determined lack of production or production of a variant protein determines an individual’s lymphocytic repertoire. This in turn is the key factor in determining the potential severity of an individual’s immunological response to ERT. It also highlights the need for immunological assay standardization particularly those looking at describing the degree of functional impact, robust biochemical or clinical endpoints and detailed patient subgroup identification if the true evaluations of impact are to be realised.
KeywordsEnzyme Replacement Therapy Fabry Disease Pompe Disease Peripheral Tolerance Agalsidase Beta
Compliance with ethics guidelines
Conflict of interest
Alexander Broomfield funding for travel and consultancy from Genzyme Corporation UK (A Sanofi company) and travel grants from Shire UK and Biomarin Corporations.
Simon Jones has received Consultancy, research grants and speaking Honoraria for Genzyme Corporation UK (A Sanofi company), Biomarin, Ultragenyx, Alexion and Shire.
Brian Bigger has received grant funding for research from Shire UK Corporation.
Stephen Hughes declares no conflict of interest.
Not applicable as literature review.
This article does not contain any studies with animals performed by the authors.
- Archer LD, Langford-Smith KJ, Bigger BW, Fildes JE (2013) Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity. JIMD 37:1–12Google Scholar
- Barbier AJ, Bielefeld B, Whiteman DA, Natarajan M, Pano A, Amato DA (2013) The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase. Mol Genet Metab 110:303–310PubMedCrossRefGoogle Scholar
- Baruteau J, Broomfield A, Crook V et al (2014) Successful desensitisation in a patient with CRIM-positive infantile-onset Pompe disease. JIMD Rep 12:99–102Google Scholar
- Burton BK, Whiteman DA (2011) Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). Mol Genet Metab 103:113–120PubMedCrossRefGoogle Scholar
- Harmatz P, Ketteridge D, Giugliani R et al (2005) Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115:e681–e689PubMedCrossRefGoogle Scholar
- Harmatz P, Giugliani R, Schwartz I et al (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 148:533–539PubMedCrossRefGoogle Scholar
- Harmatz P, Giugliani R, Schwartz IV et al (2008) Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 94:469–475PubMedCrossRefGoogle Scholar
- Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E (2015) Serum-mediated inhibition of enzyme replacement therapy in fabry disease. J Am Soc NephrolGoogle Scholar
- Owen JA, Punt J, Stranford SA (2013) T cell activation, differentiation and memory. In: Owen JA, Punt J, Stranford SA (eds) Kuby Immunology 2013. W.H. Freeman and Company, New York, p 364Google Scholar
- Pandey GS, Yanover C, Howard TE, Sauna ZE (2013) Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment. PLoS Comput Biol 9, e1003066PubMedPubMedCentralCrossRefGoogle Scholar
- Richards SM, Olson TA, McPherson JM (1993) Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood 82:1402–409Google Scholar
- Santra S, Sreekantam S, Stewart C, Gould R, Vijay S. Desensitization to galsulfase for the treatement of recurrent infusion association reactions in a child with MPS VI. Mol Genet Metab 15 A.D.; 114: S101Google Scholar
- Su J, Sherman A, Doerfler PA, Byrne BJ, Herzog RW, Daniell H (2015) Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice. Plant Biotechnol J doi: 10.1111/pbi.12413Google Scholar